Drug intelligence / Profile preview

25 Ingredients Mandrake Pill

Development stage: Unknown
Lead developer: Tibet Pharmaceuticals
Administration: Oral

Overview

The **25 Ingredients Mandrake Pill** is a commercialized traditional Tibetan medicine product developed and marketed by Tibet Pharmaceuticals, Inc. (through its subsidiary Yunnan Shangri-La Tibetan Pharmaceutical Group Limited). It is authorized by China's State Food and Drug Administration (SFDA) for regulating menses to treat **endometritis**, **pelvic inflammations**, and **women's anemia**. Derived from natural herbs and minerals sourced from the Qinghai-Tibet Plateau, it represents a modernized formulation of Tibetan medicine aimed at women's reproductive health, with no detailed public disclosure of its specific 25 ingredients or precise mechanism of action beyond traditional uses.[1][3][7][13]

Brand names: 25 Ingredients Mandrake Pill

Beyond the preview

Go deeper on 25 Ingredients Mandrake Pill.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 25 Ingredients Mandrake Pill.

Explore the full profile